NASDAQ: MBAICheck Cap Ltd Stock
$1.41-0.02 (-1.4%)
Updated Aug 7, 2026
MBAI Price
$1.41
Fair Value Price
-$0.00
Market Cap
$9.90M
52 Week Low
$0.60
52 Week High
$3.92
P/E
2.14x
P/B
2.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$4.14M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.18
Operating Cash Flow
-$46k
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MBAI Overview
Check-Cap Ltd. is a medical diagnostics entity currently in its clinical development phase, dedicated to advancing screening solutions that utilize capsule-based technology. This firm was established in 2004 and conducts its primary operations from Isfiya, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MBAI's potential to beat the market
- MBAI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
MBAI
RankedUnranked of 41
RankedUnranked of 41
Be the first to know about important MBAI news, forecast changes, insider trades & much more!
MBAI News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MBAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MBAI ($1.41) is overvalued by 62,867.42% relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MBAI ($1.41) is not significantly undervalued (62,867.42%) relative to our estimate of its Fair Value price of -$0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MBAI is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more MBAI due diligence checks available for Premium users.
Valuation
MBAI fair value
Fair Value of MBAI stock based on Discounted Cash Flow (DCF)
Price
$1.41
Fair Value
-$0.00
Undervalued by
62,867.42%
MBAI ($1.41) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MBAI ($1.41) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MBAI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.14x
Industry
9.79x
Market
13.41x
MBAI is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MBAI is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
MBAI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.88x
Industry
4.27x
MBAI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MBAI's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MBAI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.5M
Liabilities
$4.0M
Debt to equity
1.18
MBAI's short-term liabilities ($4.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MBAI's short-term assets ($219.00k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MBAI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MBAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
MBAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MBAI vs Diagnostic & Research Stocks
Check Cap Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.